Two vs three doses of human papillomavirus vaccine: New policy for the second decade of the vaccination program
Mené auprès de 1 518 participants, cet essai international évalue, du point de vue de l'immunogénicité, la non infériorité de deux doses de vaccin nonavalent anti-papillomavirus humain chez les filles et garçons âgés de 9 à 14 ans par rapport à trois doses de ce même vaccin chez les adolescentes et jeunes femmes âgées de 16 à 26 ans
This year marks the 10th year of the human papillomavirus (HPV) vaccination program in the United States. In 2006, the first HPV vaccine, quadrivalent HPV vaccine, was licensed by the US Food and Drug Administration and recommended by the Advisory Committee on Immunization Practices and the US Centers for Disease Control and Prevention (CDC). In subsequent years, 2 additional HPV vaccines were licensed, bivalent HPV vaccine in 2009 and 9-valent HPV vaccine in 2014.1 All 3 vaccines were initially licensed and recommended for use in a 3-dose series. In 2006, vaccination was recommended for girls at the age of 11 or 12 years with catch-up vaccination through the age of 26 years; in 2011, the United States was the first country to include boys and men in the routine HPV vaccination program. Following national introductions of HPV vaccination, significant declines in vaccine-type HPV prevalence, genital warts, and cervical precancers have been observed in the United States and other countries.2
JAMA , éditorial en libre accès, 2015